N-Methylbenzimidazoles as mIDH1 inhibitors

US10370339B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Sven Ring · Jena, DE
• Olaf Panknin · Berlin, DE
• Katja Zimmermann · Mülheim an der Ruhr, DE
• Judith Günther · Berlin, DE
• Lars Bärfacker · Oberhausen, DE

Key dates

• Filing date: Jun 3, 2016
• Grant date: Aug 6, 2019
• Expiry date: Jun 3, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C229/42
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.